

CE 6 Methodologies in Human Health Risk Assessment

Q. J. Zhao¹, B. Meek², H. A. Barton³ and J. C. Lipscomb¹. ¹US EPA, Cincinnati, OH, ²University of Ottawa, Ottawa, ON, Canada and ³Pfizer Inc., Groton, CT.

This course provides an overview of more advanced aspects of chemical risk assessment, following up from a successful CE course on basic principles offered at the Annual Meeting in 2013. This new course will focus on methodologies, which incorporate increased use of biological and chemical specific data as a basis to provide more accurate estimates of risk. In addition, it will address evolving areas such as problem formulation as a basis to better target toxicity testing and tailor assessments to the needs of risk management. The course will feature presentations and discussions focusing on the value of mode of action analysis for characterization of hazard, the fundamental tenets of physiologically based pharmacokinetic (PBPK) model development and implementation, use of benchmark dose (BMD) models to identify points of departure, and use of chemical specific adjustment factors to address inter- and intraspecies uncertainty and variability. The principles and key components of these methodologies will be illustrated with applied case examples from the regulatory risk assessment arena.

CE 7 Nonclinical Animal Models Enabling Biopharmaceutical Advances in Translational Medicine

T. M. Monticello¹, R. Dixit², S. Morgan³, N. Ganerup⁴, V. J. Kadambi⁵ and J. T. Sullivan¹. ¹Amgen Inc., Thousand Oaks, CA, ²MedImmune, Gaithersburg, MD, ³Abbvie, Abbott Park, IL, ⁴Ellegaard Göttingen Minipigs AIS, Dalmose, Denmark and ⁵Millennium, Cambridge, MA.

A fundamental theme in drug discovery and nonclinical development is the utilization of appropriate animal models that are predictive for efficacy or adverse events in humans administered a novel biopharmaceutical. The accurate prediction of human adverse effects using nonclinical animal toxicology studies remains a major goal in drug development and relies on appropriate animal models. Essential attributes for an appropriate animal model include similar target distribution, target pharmacology, systemic pharmacokinetics, metabolism, and distribution to those of humans. Utilization of the most appropriate animal model aligns with the 2011 US FDA Strategic Plan to advance regulatory science and modernize toxicology in order to enhance product safety and develop better models of human adverse responses. The Preclinical Safety Leadership Group (PSLG) of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) is creating a contemporary industry-wide database to determine accuracy with which the interpretation of nonclinical safety assessments in animal models correctly predicts human risk. The course will present considerations for the selection of an appropriate animal model for nonclinical safety, the use of animal models of disease in safety testing, emerging use of the minipig in safety testing, data from an industry-wide nonclinical to clinical translational database, and the use of animal safety data in the design and conduct of clinical trials. Output from the course will help identify advances and remaining gaps in the utilization of animal models in biopharmaceutical development.

CE 8 Nanotoxicology: Past Achievements, Future Challenges, and Potential Solutions

S. M. Hussain¹, D. B. Warheit², L. K. Braydich-Stolle¹, C. Grabinski¹, K. K. Comfort³ and C. Geraci¹. ¹US Air Force, Wright-Patterson AFB, OH, ²DuPont Haskell Laboratories, Newark, DE, ³University of Dayton, Dayton, OH and ⁴CDC-NIOSH, Cincinnati, OH.

Nanomaterials (NM) possess tremendous promise to advance consumer, military, and medical applications due to their unique physicochemical properties, such as enhanced surface area, tunable size, modifiable surface chemistry, and particle reactivity. However, these same properties have made NMs a potential health hazard, thus giving rise to the field of nanotoxicology (NT), which has become a prominent player in toxicological advancement and research over the past decade. Initial NT studies were limited by a lack of both available materials and characterization tools. Through advances in material science, enhanced capabilities have been developed that allow for the synthesis of distinctive NMs and the ability to accurately evaluate their characteristics. Taking advantage of these developments, NT has made remarkable progress in evaluating the hazards of NMs and correlating specific properties, such as size, shape, coating, and composition, to observe cytotoxicity. However, even with these numerous advances, there are still a number of constraints plaguing the field of NT. One principal area of concern is the development of procedures that account for new NT facets; including NM behavior in a physiological environment, varied aggregate structure, role of ionic dissolution, and realistic modes of exposure. Another limitation is the need for new and more

powerful characterization tools. Recently, the question of dosimetry has become a forefront topic and whether a universal, conceptual standard should be adopted, such as mass, surface area, or particle number. Arriving at a consensus on this issue is critical for the establishment of NM exposure limits and risk assessment metrics, which are significantly lacking. To accomplish accurate risk assessment and regulatory evaluations, NT will have to develop a means to improve the correlation of *in vitro* data to *in vivo* predictions, via enhanced cell models, relevant dosages (low vs. high), and realistic exposure scenarios. This CE course will evaluate where NT stands, by highlighting key research successes, identifying challenges facing the field today, and exploring solutions to overcome current limitations.

CE 9 Epidemiology for Toxicologists: What the Numbers Really Mean

N. B. Beck¹, M. Goodman², S. Eftim³, J. E. Goodman⁴ and J. Bus⁵. ¹American Chemistry Council, Washington, DC, ²Emory University, Atlanta, GA, ³George Washington University School of Public Health, Fairfax, VA, ⁴Harvard School of Public Health and Gradient, Cambridge, MA and ⁵Exponent, Midland, MI.

21st Century risk assessment relies on data from multiple lines of evidence. High quality human epidemiology data are generally preferred for regulatory decision-making, but the body of evidence often includes animal toxicity, *in vitro*, *in silico*, animal dosimetry, and human exposure data. The quality of individual epidemiology studies can be highly variable and dependent on study design as well as other critical factors that sometimes cannot be controlled for. For risk assessors to fully understand the implications of epidemiology evidence, they must understand how the overall integration of toxicity and mechanistic data with human epidemiology findings facilitates science-informed decision-making. A sufficient understanding of the epidemiology data is a necessary starting point for appropriately integrating all the available information. The course is geared towards the toxicologist who is trying to determine how to appropriately evaluate, use, and integrate epidemiology data in a weight-of-evidence evaluation or risk assessment. Attendees first will be given a basic overview of epidemiology, with a focus on different epidemiology study designs and their strengths and weaknesses. Attendees will also gain an understanding of exposure assessment and biomonitoring, and how this information is used and evaluated in epidemiology studies. Additional learning objectives of the course: How to determine when an association may be supportive of a causal relationship and what confidence intervals mean; how to use trend information; how to evaluate and understand adjustments that are made for potential confounding factors; and how to evaluate several epidemiology studies on the same topic, particularly in light of available toxicity and mechanistic data. Finally, attendees will learn to integrate all types of data streams with a real example. Attendees will leave the course with a stronger understanding of how to interpret and use epidemiology data in their weight-of-evidence analyses and risk assessments, and how epidemiology can help inform regulatory decision-making.

CE 10 Innovations in Methodologies for Inhalation Exposure and Interpretations of *In Vivo* Toxicity

J. Pauluhn², J. D. McDonald³, B. T. Chen⁴, T. E. Kleindienst¹ and M. A. Higuchi¹. ¹US EPA, Research Triangle Park, NC, ²Bayer HealthCare, Wuppertal, Germany, ³Lovelace Respiratory Research Institute, Albuquerque, NM and ⁴NIOSH, Morgantown, WV.

The respiratory system presents most diverse structural and cellular heterogeneity suited to handle complicated aspects of air liquid interface such as the direct exposure of the delicate cellular and capillary surfaces to the atmosphere and the encounter of lung epithelial cells to complex mixtures of particles and gases. Not only the respiratory depositions of inhaled substances vary regionally but also the regional responses generated by the respiratory tract. Recently the field of inhalation technology and respiratory toxicology has seen revolutionary growth because of the emergence of the use of nanomaterials and renewable energy sources creating new environmental challenges. Moreover, the paradigm shift of toxicology testing to high throughput screening has led to the development of novel inhalational approaches for cells. Speakers will cover the recent advances in inhalation methodologies for various types of emerging inhalants and focus on generation of atmospheres for *in vivo* and *in vitro* toxicity assessment. These aerosols will include gas and particulate emissions from vehicles using old and new energy sources, forest fires, coal combustion, manufactured nanomaterials and mixtures formed from atmospheric aging. The dynamic of physicochemical composition of such mixed aerosols will be discussed to allow for identification of causative constituents and lung site-specific injuries. Structural differences in the respiratory tract of rodents and large mammals, including humans, impacting dosimetry will be discussed. Respiratory system heterogeneity between humans and animals, and their differential neurohumoral mechanisms will be discussed to aid in interpretation of inhalational hazard for

humans. This course will be useful for those involved in air pollution toxicology, nanotoxicology, novel drug delivery systems, pulmonary toxicology, and risk assessment.

CE 11 **Nonclinical Pediatric Drug Development: Considerations, Study Designs, and Strategies**

K. E. Thompson¹, E. M. Lewis², K. Davis-Bruno³, J. Carleer⁴, S. B. Laffan⁵ and G. J. Chellman⁶. ¹*Bristol-Myers Squibb Company, New Brunswick, NJ*, ²*Charles River Laboratories, Horsham, PA*, ³*US FDA, Silver Spring, MD*, ⁴*Belgian Federal Agency for Medicines and Health Products, Brussels, Belgium*, ⁵*GlaxoSmithKline, King of Prussia, PA* and ⁶*Charles River Laboratories, Reno, NV*.

Although nonclinical and clinical testing needs for drugs for pediatric populations have been discussed for more than 40 years, there is no default approach to evaluating safety in this age group. Over the last decade there has been a heightened awareness of the differences between the pediatric and adult patient, and these differences are being addressed by the pharmaceutical and healthcare industries, as well as the governmental and regulatory bodies that sanction the development and testing of drugs for children. As regulatory demands evolve for nonclinical safety assessments in juvenile animals, industry leaders are developing innovative ways to meet the regulatory expectations and to overcome the challenges associated with pediatric drug development. Many practical issues regarding nonclinical testing in immature animals have been surmounted, using novel and/or adapted approaches. There are considerations related to the differences in regional guidelines (US FDA, EU, and Japan), therefore development of appropriate information for submission to worldwide agencies is critical. History and experience provide the best scientific arguments as to why juvenile animals can be useful. There are numerous examples of drugs that have identified findings in various species, including information regarding kinetic and toxicity differences that highlight considerations regarding nonclinical testing models. Additionally, there are unique challenges associated with nonclinical juvenile toxicity testing for biopharmaceuticals, including selection of appropriate animal models, immunogenicity, dose selection (toxicity vs. pharmacology), and relevant endpoints. Developing a juvenile animal program requires an appreciation of the complexity of the nonclinical strategies to enable pediatric trials and an overview of the historical perspective and the current approaches to evaluating safety during this unique period of life.

CE 12 **Stem Cells in Toxicology**

E. J. Tokar¹, M. P. Waalkes¹, R. Deans² and K. L. Kolaja³. ¹*NIEHS, Research Triangle Park, NC*, ²*Athersys Inc., Cleveland, OH* and ³*Cellular Dynamics International, Montclair, NJ*.

Stem cells are revolutionizing toxicological research and remain an area with tremendous potential. Recently, research on stem cells has generated tremendous public and professional interest. However, some areas of toxicological research have lagged behind in the integration of stem cells as a concept in toxicant-induced disease etiology. We will describe the utility and suitability of the assorted types of stem cell models (i.e. embryonic, fetal, progenitor, induced pluripotent, immortalized stem cell lines, etc.) for various research purposes, including disease modeling, drug discovery and toxicity testing in order to describe the potential applications of stem cells in toxicological research. This important overview of stem cells will highlight their nomenclature, properties, and their roles in the genesis of various diseases.

CE 13 **Translational Biomarkers in the Assessment of Health and Disease**

V. S. Vaidya¹, M. Moses⁴, D. L. Mendrick², J. Aubrecht³ and C. Leptak⁵. ¹*Harvard Medical School, Boston, MA*, ²*US FDA-NCTR, Jefferson, AR*, ³*Pfizer Inc., Groton, CT*, ⁴*Children's Hospital Boston, Boston, MA* and ⁵*US FDA, Silver Spring, MD*.

Biomarkers serve as quantitative measures of chemical exposures and biologically effective doses, early warning signals of biologic effect, predict outcome in a patient with disease, and identify who will respond to an intervention and whether the intervention is working. The current era of scientific discovery has brought seemingly limitless opportunities for improvements in medical care. Translational biomarkers that can be measured in blood or urine in both experimental animals and man are of particular interest. Given the importance to the clinical, pharmaceutical, and regulatory communities motivated by more specific and timely diagnoses, early intervention and safer therapies, clinically useful biomarkers have evolved over time, reflecting the scientific and technological progress made over the centuries. An in-

creasing number of clinically relevant tests and procedures are available to estimate organ injury and guide treatment. The use of molecular signals in the assessment of health and disease is not new; however, the concept of what constitutes a useful biomarker has evolved considerably in the past two to three decades given the advanced enabling technologies, deeper molecular understanding of disease, and the advent of a regulatory framework for biomarker qualification. Our panel experts will highlight the potential of these biomarkers over a wide variety of applications spanning preclinical-clinical safety in liver and kidney, to disease monitoring in cancer. The panel will also demonstrate the application of translational biomarkers in clinical trial design. Coordinated efforts at biomarker discovery and validation as well as technologies for biomarker measurement will help ensure that the ultimate goal of safer drugs, a cleaner environment, and improved patient outcomes are realized.

S 14 **Air Pollution and Cardiovascular Effects: Mechanisms and Role of Lipid Peroxidation**

D. J. Conklin. *Cardiovascular Medicine, University of Louisville, Louisville, KY*.

The mechanisms by which air pollution, including particulate matter (PM_{2.5}) and volatile gases, affect human cardiovascular health are incompletely known. Yet many animal studies performed to probe these mechanisms have observed changes in the levels of lipids and/or lipid peroxidation products regardless of the specific form of air pollution, e.g., diesel engine exhaust, concentrated ambient particulate matter, or volatile gases, used in the exposure that associates with severity of injury. These studies suggest a potential common pathway of injury that is dependent on oxidative stress and an increased production of lipid mediators. The role of lipids and lipid peroxidation as final common mediators of air pollution-induced injury in the cardiovascular system is the focus of this symposium. Speakers will address how exposures to diverse types of air pollutants, including complex mixtures, traffic emissions, volatile acrolein, and concentrated ambient particulate matter, result in alterations in circulating lipid levels, lipids structure and function, and lipid peroxidation products in target organs including lungs, blood, and the vasculature. Collectively, these presentations will shed light on the specific role of lipids and lipid peroxidation in air pollution-induced cardiovascular injury.

S 15 **Air Pollution, Lipid Oxidation, and Cardiovascular Effects in Humans and Animals Models**

A. Bhatnagar. *Cardiovascular Medicine, University of Louisville, Louisville, KY*.
Sponsor: D. Conklin.

Epidemiological studies indicate that ambient air pollution enhances the incidence and progression of cardiovascular disease and increases the risk of cardiovascular mortality primarily by promoting acute coronary syndromes and ischemic heart disease. Exposure to air pollutants associates with systemic lipid peroxidation, which has been shown to be an important marker and pathogenic mediator of atherosclerosis, acute plaque rupture and myocardial infarction. This symposium will address the relationship between air pollutants and lipid peroxidation that often accompanies exposures resulting in altered tissue and blood lipids. Moreover, this symposium will address the question whether and how these changes contribute to subsequent cardiovascular dysfunction and potentially increase the risk of cardiovascular disease.

S 16 **Vascular Lipid Peroxidation Induced by Complex Emissions Indicates Gas-Particle Interactions in Driving Systemic Toxicity**

M. Campen. *Pharmaceutical Sciences, University of New Mexico, Albuquerque, NM*.

Air pollution is associated with adverse cardiovascular events in epidemiological studies. Several recent studies have indicated a role for oxidative changes to phospholipids following inhalation of various pollutants, which leads to altered biological activity of those modified lipids. To better understand the important causal components of the ambient pollution mixtures, we have investigated the relative lipid peroxidation induced in the murine aortic wall by diverse exposure conditions involving fresh emissions of gasoline and/or diesel engines, resuspended road dust, and secondary particulates of sulfate or nitrate composition. We noted that emissions containing mixtures of particulate and gas phase components typically induced greater vascular lipid peroxidation than did individual components. Moreover, our data suggest that gases may deposit on particulates, thereby driving toxicity in a surface area-dependent manner. Further studies highlight a role for modified lipids and metabolites in the circulation after exposures, in human and rodent studies, that may drive the accumulation of vascular lipid peroxides.

The Toxicologist

Supplement to *Toxicological Sciences*

53rd Annual Meeting and ToxExpo™

March 23-27, 2014 • Phoenix, Arizona



OXFORD
UNIVERSITY PRESS

ISSN 1096-6080
Volume 138, Issue 1
March 2014

www.toxsci.oxfordjournals.org

An Official Journal of
the Society of Toxicology

SOT | Society of
Toxicology

Creating a Safer and Healthier World
by Advancing the Science of Toxicology

www.toxicology.org